Pernicious anemia is a specific form of megaloblastic anemia caused by vitamin B12 deficiency secondary to an autoimmune disruption of gastric absorption processes. It represents a clinically and pathogenetically distinct subtype among vitamin B12 deficiency anemias, characterized by autoimmune destruction of gastric parietal cells and consequent reduced production of intrinsic factor (IF), an essential glycoprotein for cobalamin absorption in the intestine.
It is not simply a nutritional deficiency of vitamin B12, but rather a true systemic autoimmune disease, often associated with other autoimmune conditions and carrying specific risks such as increased susceptibility to gastric neoplasms and earlier, more severe neurological manifestations compared to other forms of vitamin B12 deficiency.
For a general discussion on vitamin B12 absorption mechanisms, common symptoms of its deficiency, and standard diagnostic-therapeutic strategies, please refer to the page on vitamin B12 deficiency anemia.
Pathophysiology of Pernicious Anemia
The pathophysiology of pernicious anemia is based on a combination of autoimmune factors irreversibly impairing the normal physiology of vitamin B12 absorption. Under normal conditions, dietary vitamin B12 is released in the stomach and binds to intrinsic factor, subsequently being absorbed in the ileum via specific receptors. Absence or dysfunction of intrinsic factor renders this absorption process ineffective, leading to progressive depletion of the body's cobalamin stores.
In pernicious anemia, the autoimmune damage targets both the intrinsic factor and the gastric parietal cells:
Anti-intrinsic factor antibodies: neutralize the binding between IF and vitamin B12 or inhibit the interaction of the IF-B12 complex with ileal receptors, preventing enteric absorption of the vitamin.
Anti-parietal cell antibodies: cause progressive autoimmune destruction of cells producing IF and hydrochloric acid, leading to autoimmune atrophic gastritis with achlorhydria.
The loss of gastric acidity (hypochlorhydria or achlorhydria) is not secondary but an integral part of the disease mechanism, as it also impairs the initial release of vitamin B12 from dietary proteins, further exacerbating the deficiency.
As the disease progresses, gastric mucosal atrophy may become complete, with fibrotic replacement of glands and permanent reduction in intrinsic factor production. This explains why, unlike other forms of vitamin B12 deficiency, pernicious anemia requires lifelong parenteral vitamin B12 supplementation, as the absorption defect is irreversible.
Immunopathological Features and Associations with Other Autoimmune Diseases
Pernicious anemia belongs to the group of organ-specific autoimmune diseases. Its presence is frequently associated with other autoimmune conditions, suggesting a systemic alteration of immune tolerance mechanisms.
The main associated conditions include:
Hashimoto's thyroiditis: common association, part of the type 2 autoimmune polyendocrine syndrome spectrum.
Type 1 diabetes mellitus: shares genetic predisposition factors (HLA-DR3 and DR5 alleles).
Vitiligo and Addison's disease: further signs of systemic autoimmunity.
Myasthenia gravis and systemic lupus erythematosus (less frequent).
These associations necessitate a systematic screening for other autoimmune diseases, especially endocrine disorders, in all patients diagnosed with pernicious anemia.
From an immunological standpoint, pernicious anemia is characterized by the presence of specific autoantibodies in the serum:
Anti-intrinsic factor antibodies: found in about 60-70% of cases, highly specific but less sensitive.
Anti-gastric parietal cell antibodies: present in up to 90% of cases, but less specific (also found in other forms of atrophic gastritis).
The detection of these autoantibodies, while not mandatory for clinical diagnosis, represents a strong supportive diagnostic element.
Specific Clinical Manifestations
The clinical manifestations of pernicious anemia reflect the dual damage caused by vitamin B12 deficiency and underlying autoimmune atrophic gastritis. Although many signs and symptoms are shared with other forms of vitamin B12 deficiency anemia, certain clinical features are particularly distinctive.
Hematologic Manifestations
As in other megaloblastic anemias, the following are observed:
Macrocytic anemia: large, fragile red blood cells with reduced oxygen-carrying capacity.
Pancytopenia: in advanced cases, reduction in white blood cells and platelets due to ineffective bone marrow hematopoiesis.
Hemolytic signs: mild elevation of LDH and indirect bilirubin levels due to intramedullary destruction of erythroid precursors.
Neurological Manifestations
Neurological abnormalities tend to be earlier and more severe compared to other causes of vitamin B12 deficiency:
Subacute combined degeneration of the spinal cord: simultaneous impairment of the posterior columns (vibration and proprioception sense) and lateral corticospinal tracts (motor functions).
Distal paresthesias, sensory ataxia, and positive Romberg sign.
Cognitive impairment: in some cases evolving into a reversible dementia-like state.
Muscle weakness and hypotonia.
Importantly, neurological damage may precede the development of anemia and may become irreversible if treatment is delayed.
Gastrointestinal and Oral Manifestations
Autoimmune atrophic gastritis underlying pernicious anemia may cause:
Hunter's glossitis: smooth, reddened, and painful tongue.
Chronic dyspepsia: persistent epigastric discomfort and slow digestion.
Moderate unintentional weight loss in advanced stages.
Neoplastic Risk
Pernicious anemia is recognized as an independent risk factor for developing:
Gastric adenocarcinoma: approximately 2–3 times higher risk than the general population.
Thus, patients with pernicious anemia require regular endoscopic surveillance with targeted gastric mucosal biopsies.
Diagnosis
The diagnosis of pernicious anemia requires an integrated approach combining clinical evidence of vitamin B12 deficiency with immunological and histological confirmation of underlying autoimmune gastritis.
Clinical Diagnosis
The suspicion should arise in patients with macrocytic anemia, neurological symptoms, glossitis, or chronic dyspepsia, especially when risk factors such as advanced age or a family history of autoimmune diseases are present.
Laboratory Tests
Key laboratory investigations include:
Serum vitamin B12 levels: levels below 200 pg/mL are highly suggestive; borderline cases require methylmalonic acid and homocysteine assays, both elevated in functional deficiency.
Complete blood count: showing macrocytic anemia (elevated MCV) often associated with pancytopenia.
Peripheral blood smear: demonstrating megalocytes, anisopoikilocytosis, and hypersegmented neutrophils.
Elevated LDH and indirect hyperbilirubinemia: markers of intramedullary hemolysis.
Immunological Tests
To confirm the autoimmune nature of the disorder, the following are recommended:
Anti-intrinsic factor antibodies (anti-IF): positive in about 70–85% of cases, highly specific for pernicious anemia.
Anti-gastric parietal cell antibodies: positive in more than 90% of cases, although less specific (may be present in other forms of atrophic gastritis).
The presence of anti-IF antibodies virtually confirms the diagnosis of pernicious anemia.
Endoscopic and Histological Examinations
Gastroscopy with biopsies from the antrum and fundus is fundamental to document:
Autoimmune atrophic gastritis: characterized by the atrophy of oxyntic glands and lymphocytic infiltration of the lamina propria.
Intestinal metaplasia or dysplasia: potential precursors of neoplastic transformation.
Exclusion of precancerous or malignant gastric lesions (e.g., adenocarcinoma, carcinoid tumors).
Logical Diagnostic Sequence
In a patient with macrocytic anemia and suspected vitamin B12 deficiency, the correct sequence is:
Serum vitamin B12 measurement.
If inconclusive, assess methylmalonic acid and homocysteine levels.
Screening for anti-intrinsic factor and anti-parietal cell antibodies.
Gastroscopy with multiple biopsies to confirm autoimmune atrophic gastritis and assess gastric mucosal status.
If vitamin B12 deficiency is confirmed but antibodies and gastroscopy are non-diagnostic, alternative causes of malabsorption (e.g., ileal resection, intestinal infections, drugs) must be investigated.
Treatment
Treatment of pernicious anemia is based on lifelong correction of vitamin B12 deficiency and long-term monitoring for gastric complications.
Vitamin B12 Supplementation
The standard treatment consists of intramuscular administration:
Initial phase: 1000 mcg of hydroxocobalamin or cyanocobalamin IM daily for 1 week.
Consolidation phase: 1000 mcg IM once weekly for 4–6 weeks.
Maintenance phase: 1000 mcg IM monthly for life.
High-dose oral therapy (≥1000–2000 mcg/day) may be considered only in highly adherent patients without severe neurological deficits. However, parenteral administration remains the preferred route due to the intrinsic absorption defect.
Monitoring Therapeutic Response
Reticulocyte crisis within 5–7 days after starting therapy.
Progressive rise in hemoglobin, with normalization expected within 6–8 weeks.
Clinical monitoring of neurological symptoms: improvement may take weeks to months and may be incomplete if treatment is delayed.
Management of Gastric Atrophy and Oncologic Surveillance
Given that autoimmune atrophic gastritis is a recognized precursor for gastric cancer, the following are recommended:
Periodic gastroscopy every 3–5 years, or more frequently if intestinal metaplasia or dysplasia is present.
Helicobacter pylori eradication if detected, to reduce oncogenic risk.
Patient education on early signs of gastric neoplasia (e.g., worsening anemia, new-onset epigastric pain, unexplained weight loss).
Prognosis and Complications
With appropriate and continuous vitamin B12 replacement therapy, the hematologic prognosis of pernicious anemia is excellent. However, some important risks persist:
Residual neurological damage: untreated for a long time, neurological deficits such as ataxia, cognitive disturbances, and peripheral neuropathies may remain.
Gastric neoplasms: increased risk of gastric adenocarcinoma and carcinoid tumors necessitates lifelong surveillance.
Development of other autoimmune diseases: commonly associated conditions include autoimmune thyroiditis, type 1 diabetes, and autoimmune adrenal insufficiency (autoimmune polyendocrine syndrome).
Careful long-term hematologic, neurologic, and gastroenterologic follow-up is essential to ensure the best possible quality of life for patients with pernicious anemia.
For a complete overview of vitamin B12 metabolism, intestinal absorption, and general aspects of cobalamin deficiency anemias, please refer to the page: Vitamin B12 Deficiency Anemia.
References
O'Leary F, Samman S. Vitamin B12 in health and disease. Nutrients. 2010;2(3):299-316.
Stabler SP. Clinical practice. Vitamin B12 deficiency. New England Journal of Medicine. 2013;368(2):149-160.
Lindenbaum J, Savage DG, Stabler SP, Allen RH. Diagnosis of cobalamin deficiency: II. Relative sensitivities of serum cobalamin, methylmalonic acid, and total homocysteine concentrations. American Journal of Hematology. 1990;34(2):99-107.
O'Connell TX, Velanovich V. Review of the diagnosis and management of pernicious anemia. American Journal of Surgery. 1999;177(5):431-436.
Kaptan K, Beyan C, Ural AU, et al. Helicobacter pylori – Is it a novel causative agent in vitamin B12 deficiency?Archives of Internal Medicine. 2000;160(9):1349-1353.
Carmel R. Current concepts in cobalamin deficiency. Annual Review of Medicine. 2000;51:357-375.
Carmel R. Pernicious anemia: new insights from a century of study. Hematology/Oncology Clinics of North America. 2008;22(2):311-328.
Andrès E, Affenberger S, Zimmer J, et al. Current hematological findings in cobalamin deficiency: a study of 201 consecutive patients with documented cobalamin deficiency. Clinical and Laboratory Haematology. 2006;28(1):50-56.
Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis: pathogenesis, pathology and management. Nature Reviews Gastroenterology & Hepatology. 2013;10(9):529-541.
